Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

  1. Ludwig, H.
  2. Moreau, P.
  3. Dimopoulos, M.A.
  4. Mateos, M.-V.
  5. Kaiser, M.
  6. Hajek, R.
  7. Feng, S.
  8. Cocks, K.
  9. Buchanan, J.
  10. Weisel, K.
Aldizkaria:
Blood Cancer Journal

ISSN: 2044-5385

Argitalpen urtea: 2019

Alea: 9

Zenbakia: 3

Mota: Artikulua

DOI: 10.1038/S41408-019-0181-0 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak